DUBLIN--(BUSINESS WIRE)--The "Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease,historical &forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Warm Autoimmune Hemolytic Anemia (WAIHA) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Warm Autoimmune Hemolytic Anemia (WAIHA) - Disease Understanding and Treatment Algorithm
Warm Autoimmune Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs which can be idiopathic (primary) or secondary. In w-AIHA, the autoantibodies react optimally with the RBCs at 37C. In typical cases, no specific antibody can be identified since theyare polyclonal and react with all RBCs tested (pan-reactive), even when w-AIHA complicates a clonal B-cell lymphoproliferative disorder like CLL. The traditional treatment options for WAIHA include corticosteroids, splenectomy,and conventional immunosuppressive drugs.
The Warm Autoimmune Hemolytic Anemia (WAIHA) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Warm Autoimmune Hemolytic Anemia.
Warm Autoimmune Hemolytic Anemia Epidemiology
The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA) scenario of Warm Autoimmune Hemolytic Anemia (WAIHA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
According to the publisher, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (WAIHA) in 7 MM was found to be 82,045 in the year 2017.
Warm Autoimmune Hemolytic Anemia Drug Chapters
This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, affected individuals are usually treated with corticosteroid drugs such as prednisone and can usually be well controlled with proper treatment. For individuals who do not respond to corticosteroid therapy or develop intolerable side effects, immunosuppressive drugs may be administered, or surgical removal of the spleen (splenectomy) may be performed. Over the years,however, newer options have become available with considerable evidence of success. They are used mainly in patients who fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids.
Warm Autoimmune Hemolytic Anemia Market Outlook
The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the market of Warm Autoimmune Hemolytic Anemia in 7MM was found to be USD 368 Million in 2017, and is expected to increase during the course of the study period (2017-2030). The market for Warm Autoimmune Hemolytic Anemia is expected to increase with a CAGR of 5.20% for 7MM. Among the 7MM, the United States accounts for the largest market size of WAIHA, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Key Benefits
- This report will help to develop Business Strategies by understanding the trends shaping and driving Warm Autoimmune Hemolytic Anemia market
- Organize sales and marketing efforts by identifying the best opportunities for Warm Autoimmune Hemolytic Anemia market
- To understand the future market competition in the Warm Autoimmune Hemolytic Anemia market.
Companies Mentioned
- Rigel Pharmaceuticals
- Apellis Pharmaceuticals, Inc.
- Momenta Pharmaceuticals
- Immunovant
- Alexion Pharmaceuticals, Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hjvs8b
